Alitretinoin topical - Ligand Pharmaceuticals

Drug Profile

Alitretinoin topical - Ligand Pharmaceuticals

Alternative Names: 9-cis Retinoic acid; 9-CRA; ALRT 1057; LG 1057; LGD 1057; LGN 1057; Panretin

Latest Information Update: 17 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Kaposi's sarcoma

Most Recent Events

  • 13 Mar 2015 Launched for Kaposi's sarcoma in Argentina (Topical) before March 2015
  • 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
  • 06 Nov 2006 Eisai has completed the acquisition agreement for exclusive global rights to alitretinoin 0.1% gel from Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top